Identification of an Immune-related Signature for the Prognosis of Uveal Melanoma

Overview

Journal Int J Ophthalmol

Specialty Ophthalmology

Date 2020 Apr 21

PMID 32309184

Citations 9

Authors

Ying-Zi Li

Ying Huang

Xiang-Yang Deng

Chang-Sen Tu

Affiliations

Soon will be listed here.

Abstract

Aim: To construct an immune-related prognostic signature (IPS) that can distinguish and predict prognosis in uveal melanoma (UM).

Methods: The transcriptomic data and clinicopathological information of 80 UM patients were extracted from the TCGA database. These patients were randomly assigned to a training and a testing set.

Results: Lasso Cox analysis was performed for the prognostic immune-related genes to develop an IPS for UM in the training set. The signature was validated in both the testing set and entire cohort. We confirmed the prognostic value of our IPS in distinct subgroups and found its association with the T stage and basal diameter of the tumor. Tumor Immune Estimation Resource database analysis revealed that the IPS was negatively correlated with the infiltration of neutrophils and dendritic cells, but positively correlated with the infiltration level of CD8+ T cells. In addition, we demonstrated that immune checkpoints containing PD-1, CTLA-4, IDO, and TIGIT were moderately associated with the IPS.

Conclusion: This is the first study to develop and validate an immune-related signature with the ability of predicting prognosis for UM patients. Further studies are needed to validate its prediction accuracy.

Citing Articles

Diurnal rhythm-modulated transcriptome analysis of meibomian gland in hyperlipidemic mice using RNA sequencing.

Zhang Q, Su J, Chen J, Wu S, Qi X, Chu M Int Ophthalmol. 2025; 45(1):57.

PMID: 39890715 DOI: 10.1007/s10792-025-03431-7.

Identification and validation of immunogenic cell death-related score in uveal melanoma to improve prediction of prognosis and response to immunotherapy.

Li X, Kang J, Yue J, Xu D, Liao C, Zhang H Aging (Albany NY). 2023; 15(9):3442-3464.

PMID: 37142279 PMC: 10449274. DOI: 10.18632/aging.204680.

Identification of a prognostic six-immune-gene signature and a nomogram model for uveal melanoma.

Yang B, Fan Y, Liang R, Wu Y, Gu A BMC Ophthalmol. 2023; 23(1):2.

PMID: 36597071 PMC: 9809105. DOI: 10.1186/s12886-022-02723-1.

Recent Advances and Challenges in Uveal Melanoma Immunotherapy.

Fu Y, Xiao W, Mao Y Cancers (Basel). 2022; 14(13).

PMID: 35804863 PMC: 9264803. DOI: 10.3390/cancers14133094.

Integrative analysis identifies key genes related to metastasis and a robust gene-based prognostic signature in uveal melanoma.

Lei S, Zhang Y BMC Med Genomics. 2022; 15(1):61.

PMID: 35300699 PMC: 8932077. DOI: 10.1186/s12920-022-01211-1.

References

McLaughlin C, Wu X, Jemal A, Martin H, Roche L, Chen V . Incidence of noncutaneous melanomas in the U.S. Cancer. 2005; 103(5):1000-7. DOI: 10.1002/cncr.20866. View

Hallermalm K, De Geer A, Kiessling R, Levitsky V, Levitskaya J . Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res. 2004; 64(18):6775-82. DOI: 10.1158/0008-5472.CAN-04-0508. View

Yi Q, Zou W . A novel four‑snoRNA signature for predicting the survival of patients with uveal melanoma. Mol Med Rep. 2018; 19(2):1294-1301. DOI: 10.3892/mmr.2018.9766. View

Slater K, Hoo P, Buckley A, Piulats J, Villanueva A, Portela A . Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma. Cancer Metastasis Rev. 2018; 37(2-3):335-345. DOI: 10.1007/s10555-018-9751-z. View

Yang J, Manson D, Marr B, Carvajal R . Treatment of uveal melanoma: where are we now?. Ther Adv Med Oncol. 2018; 10:1758834018757175. PMC: 5824910. DOI: 10.1177/1758834018757175. View

Komatsubara K, Carvajal R . Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies. Curr Oncol Rep. 2017; 19(7):45. DOI: 10.1007/s11912-017-0606-5. View

Xin X, Zhang Y, Ling F, Wang L, Sheng X, Qin L . Identification of a nine-miRNA signature for the prognosis of Uveal Melanoma. Exp Eye Res. 2019; 180:242-249. DOI: 10.1016/j.exer.2019.01.004. View

Ma J, Usui Y, Takeuchi M, Okunuki Y, Kezuka T, Zhang L . Human uveal melanoma cells inhibit the immunostimulatory function of dendritic cells. Exp Eye Res. 2010; 91(4):491-9. DOI: 10.1016/j.exer.2010.06.025. View

Bhattacharya S, Andorf S, Gomes L, Dunn P, Schaefer H, Pontius J . ImmPort: disseminating data to the public for the future of immunology. Immunol Res. 2014; 58(2-3):234-9. DOI: 10.1007/s12026-014-8516-1. View

10.

Rothermel L, Sabesan A, Stephens D, Chandran S, Paria B, Srivastava A . Identification of an Immunogenic Subset of Metastatic Uveal Melanoma. Clin Cancer Res. 2015; 22(9):2237-49. PMC: 4854785. DOI: 10.1158/1078-0432.CCR-15-2294. View

11.

Ogino S, Galon J, Fuchs C, Dranoff G . Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011; 8(12):711-9. PMC: 3227751. DOI: 10.1038/nrclinonc.2011.122. View

12.

Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi A, Tanaseichuk O . Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019; 10(1):1523. PMC: 6447622. DOI: 10.1038/s41467-019-09234-6. View

13.

Ponti A, Denys A, Digklia A, Schaefer N, Hocquelet A, Knebel J . First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver. J Nucl Med. 2019; 61(3):350-356. DOI: 10.2967/jnumed.119.230870. View

14.

Singh A, Turell M, Topham A . Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011; 118(9):1881-5. DOI: 10.1016/j.ophtha.2011.01.040. View

15.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

16.

Jindal V . Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma. Chin Clin Oncol. 2018; 7(1):8. DOI: 10.21037/cco.2018.01.05. View

17.

Chua V, Aplin A . Novel therapeutic strategies and targets in advanced uveal melanoma. Curr Opin Oncol. 2017; 30(2):134-141. DOI: 10.1097/CCO.0000000000000425. View

18.

Heppt M, Heinzerling L, Kahler K, Forschner A, Kirchberger M, Loquai C . Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. Eur J Cancer. 2017; 82:56-65. DOI: 10.1016/j.ejca.2017.05.038. View

19.

Bakalian S, Marshall J, Logan P, Faingold D, Maloney S, Di Cesare S . Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin Cancer Res. 2008; 14(4):951-6. DOI: 10.1158/1078-0432.CCR-06-2630. View

20.

Chew A, Spilsbury K, Isaacs T . Survival from uveal melanoma in Western Australia 1981-2005. Clin Exp Ophthalmol. 2015; 43(5):422-8. DOI: 10.1111/ceo.12490. View